Chief Financial Officer · BeOne Medicines Ltd. (ONC)

Julia Wang

A named executive officer of BeOne Medicines in every fiscal year CompBrief holds from FY2021 to FY2022. Every figure below is printed as the company filed it and cited to the filing it came from.

Total disclosed compensation, FY2022

$6,964,043

Salary $560,000Stock awards $2,249,925

FY2021: $3,739,651

4th of 5 named executive officers at BeOne Medicines by FY2022 total.

5 named officers on file for BeOne Medicines, FY2022

Julia Wang’s pay file — $29

  • 2 fiscal years of pay, line by line
  • 5 equity grants, each cited to its filing
  • ONC’s disclosed peer group of 15 companies

A PDF and a CSV sent to your email. Every row is cited to its filing.

One-time report. No refunds.

See an example →

Velarion Intel · free for 3 days · no card

See how BeOne Medicines’s whole pay program stands against its peers

  • BeOne Medicines’s company dashboard and its AI-written, board-ready brief, every figure cited to the filing
  • Peer-group intelligence, custom peer reruns and governance screens
  • Every other company we cover, with alerts when they file
Start my free trial on ONC→

No card. Nothing is charged, and the trial ends on its own.

Compensation figures as of the proxy filed April 27, 2023 (DEF 14A).

Free

Get Julia Wang’s full pay file as a PDF — free

More than this page: up to 10 years of Julia’s pay history, a side-by-side peer comparison, and a one-page board summary — the whole file, yours now and by email.

Julia Wang compensation by year

BeOne Medicines Summary Compensation Table · all 2 fiscal years held
In US dollars, as BeOne Medicines reports it. Most recent year shaded. Totals are the company’s disclosed totals.
ComponentFY2021FY2022
Salary$445,000$560,000
Bonus$0$0
Stock awards$735,282$2,249,925
Option awards$2,206,231$3,749,918
Non-equity incentive$341,538$392,000
Pension and deferred compensation$0$0
All other$11,600$12,200
Total$3,739,651$6,964,043

Each year as stated in that year's proxy. A dash means the company reported no figure in that column. Source: BeOne Medicines Ltd. DEF 14A filed April 27, 2023, accession 0001104659-23-051427, and prior-year filings.

How this page was built: the BeOne Medicines Ltd. filed document, accession 0001104659-23-051427. Every figure is read from that document and cited to the page and table it appears in. Filed April 27, 2023.

$3.7M
$7.0M
FY21
FY22
SalaryNon-equity incentiveStock awardsOption awardsAll other

BeOne Medicines’s named executive officers, FY2022

as the company reported each
Named executive officerRoleFY2022 total
John OylerFounder, Chief Executive Officer and Chairman$18,047,667
Xiaobin WuPresident, Chief Operating Officer and General Manager of China$10,691,893
Lai WangGlobal Head of Research and Development$6,996,866
Julia Wang · this pageChief Financial Officer$6,964,043
Jane HuangFormer Chief Medical Officer, Hematology ( 16)$768,279

The full BeOne Medicines compensation record

free company brief

This page is one person within BeOne Medicines's record. The company brief lists every named executive, each linking to their own page.

Compensation, the day it’s disclosed

The CompBrief Daily Digest lists the newest executive and director compensation disclosures as companies file them.

How this record is built

Every figure on this page is one figure from a public SEC filing, printed as the filing states it and cited to the document. Compensation totals are BeOne Medicines's own disclosed totals, not summed by Velarion. Insider transactions are read from Form 4 filings and cover every line filed since the most recent proxy. Nothing is estimated by Velarion; where the company does not disclose a value the cell reads "—", and a section appears only where the company discloses the data. Corrections: records@velarion.ai.

Julia Wang's compensation dossier · One-time report. No refunds.